Non-permissiveness of synovial membrane cells to human parvovirus B19 in vitro

Miki, N.; Chantler, J. K.

doi:10.1099/0022-1317-73-6-1559

Cited by 25 publications

(14 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B19V DNA can be detected in synovial cells and fluid; however already an early report indicated that synoviocytes are nonpermissive to B19V replication [152]. In a following report, B19V DNA detected in the synovial tissues of patients with rheumatoid arthritis was specifically linked to the expression of the VP in synovium with active synovial lesions.…”

Section: Nonpermissive Systemsmentioning

confidence: 89%

“…In vitro, synoviocytes are nonpermissive to B19V [152], although they can respond to infection and assume an invasive phenotype [154] suggesting a parallel role in the pathological processes within synovia. Synovial tissues commonly harbor B19V DNA, and its mere presence is not correlated with any distinct pathological process [157,161].…”

Section: Arthritis and Rheumaticmentioning

confidence: 99%

See 1 more Smart Citation

Parvovirus B19 Achievements and Challenges

Gallinella

2013

ISRN Virology

View full text Add to dashboard Cite

Parvovirus B19 is a widespread human pathogenic virus, member of the Erythrovirus genus in the Parvoviridae family. Infection can be associated with an ample range of pathologies and clinical manifestations, whose characteristics and outcomes depend on the interplay between the pathogenetic potential of the virus, its adaptation to different cellular environments, and the physiological and immune status of the infected individuals. The scope of this review is the advances in knowledge on the biological characteristics of the virus and of virus-host relationships; in particular, the interactions of the virus with different cellular environments in terms of tropism and ability to achieve a productive replicative cycle, or, on the contrary, to establish persistence; the consequences of infection in terms of interference with the cell physiology; the process of recognition of the virus by the innate or adaptive immune system, hence the role of the immune system in controlling the infection or in the development of clinical manifestations. Linked to these issues is the continuous effort to develop better diagnostic algorithms and methods and the need for development of prophylactic and therapeutic options for B19V infections.

show abstract

Section: Nonpermissive Systemsmentioning

confidence: 89%

Section: Arthritis and Rheumaticmentioning

confidence: 99%

Parvovirus B19 Achievements and Challenges

Gallinella

2013

ISRN Virology

View full text Add to dashboard Cite

show abstract

“…NS1 has also been reported to be a transactivator of the promoter for interleukin-6, a pro-in¯ammatory cytokine [29] made by several cell types known to be adversely affected by B19 infection. Hence, NS1 protein expression could play a role in the ongoing in¯ammation and cell damage associated with persistent B19 infections in non-permissive cells such as synovial membrane cells [30]. Is NS1 expression associated with chronic disease (in particular, arthropathy) following B19 infection?…”

Section: Discussionmentioning

confidence: 99%

Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy?

Mitchell

Leong

Rosenke

2001

Journal of Medical Microbiology

View full text Add to dashboard Cite

Immune recognition of recombinant parvovirus B19 non-structural (rNS1) protein was studied by immunoblot and lymphoproliferative assays in blood from the following B19 seropositive groups: B19 infected (n 14), B19 exposed but non-infected (n 16), other illness with rash (n 3), chronic arthropathy of unknown aetiology (n 4) and healthy controls (n 7). Sera from 11 B19 seronegative subjects were also studied. Sera collected at initial diagnosis or at the time of accidental B19 exposure in pregnancy were tested for NS1 antibody and evidence of B19 DNA by nested PCR. Follow-up specimens were obtained 3±12 months later for serological, PCR and proliferation studies. B19 DNA was detected sporadically in early specimens and in one follow-up specimen from a subject who developed chronic arthropathy after B19 infection. There was no correlation with development of arthropathy. NS1-speci®c IgG was detected in early sera from B19-infected and exposed subjects but to a lesser degree in follow-up specimens, and in only one healthy control serum. No correlation with the presence of NS1-speci®c antibodies was found with development of acute or chronic arthropathy. Although lymphocyte proliferation in response to stimulation with rNS1 in vitro occurred at a higher frequency in patients who developed acute and chronic joint manifestations after B19 infection, suggesting an association with this outcome, NS1-reactive lymphocytes were also found in three B19 seronegative patients, two of whom had recently been exposed to B19 but had no illness. Hence, immune recognition of NS1 may be more indicative of recent infection with, or exposure to, parvovirus B19 than associated with development of arthropathy as previously reported.

show abstract

“…This suggests that symptoms may be due to formation of immune complexes. Despite the fact that the P antigen is expressed on synovium, it has been shown that synovial membrane cells are nonpermissive to B19 (Miki & Chantler, 1992;Cooling et al, 1995). Normal human synovial fibroblasts have been shown to exhibit increased invasiveness following exposure to B19 viraemic serum, as judged by the acquired ability to degrade reconstituted cartilage matrix (Ray et al, 2001).…”

Section: Arthropathymentioning

confidence: 99%

Advances in the biology, diagnosis and host–pathogen interactions of parvovirus B19

Corcoran

Doyle

2004

Journal of Medical Microbiology

152

103

View full text Add to dashboard Cite

Increased recognition of parvovirus B19 (B19), an erythrovirus, as a significant human pathogen that causes fetal loss and severe disease in immunocompromised patients has resulted in intensive efforts to understand the pathogenesis of B19-related disease, to improve diagnostic strategy that is deployed to detect B19 infection and blood-product contamination and, finally, to elucidate the nature of the cellular immune response that is elicited by the virus in diverse patient cohorts. It is becoming clear that at least three related erythrovirus strains (B19, A6/K71 and V9) are circulating in the general population and that viral entry into target cells is mediated by an expanding range of cellular receptors, including P antigen and â-integrins. Persistent infection by B19 is emerging as a contributory factor in autoimmune disease, a hypothesis that is constrained by the detection of B19 in the skin of apparently healthy individuals. B19 infection during pregnancy may account for thousands of incidences of fetal loss per annum in Europe, North America and beyond, yet there is currently only minimal screening of pregnant women to assess serological status, and thereby risk of infection, upon becoming pregnant. Whilst major advances in diagnosis of B19 infection have taken place, including standardization of serological and DNA-based detection methodologies, blood donations that are targeted at high-risk groups are only beginning to be screened for B19 IgG and DNA as a means of minimizing exposure of at-risk patients to the virus. It is now firmly established that a Th1-mediated cellular immune response is mounted in immunocompetent individuals, a finding that should contribute to the development of an effective vaccine to prevent B19 infection in selected high-risk groups, including sickle-cell anaemics. Parvovirus B19In 1975, Yvonne Cossart discovered what was to become known as human parvovirus B19 (B19) (Cossart et al., 1975). B19 was first associated with disease in 1981, when it was linked to an aplastic crisis in a patient with sickle-cell disease. It has since been shown to cause erythema infectiosum (EI) (fifth disease of childhood), spontaneous abortion and some forms of acute arthritis (Anderson et al., 1983; Kinney et al., 1988;Woolf & Cohen, 1995).B19 is a small, non-enveloped, ssDNA virus and, like all parvoviruses, the capsid proteins are arranged with icosahedral symmetry. B19 is 20-25 nm in diameter and has a genome of 5 . 6 kb (Clewley, 1984;Cotmore & Tattersall, 1984). The B19 capsid consists of an 83 kDa minor structural protein, VP1, and a 5 kDa major structural protein, VP2. VP2 makes up about 95 % of the total capsid, with VP1 accounting for the remaining 5 % . The sequences of the two proteins are collinear, with VP2 being identical to the carboxyl-terminus of VP1; however, VP1 comprises an additional 227 aa domain that is unique to the amino-terminal (Fig. 1). To the left of these sequences on the B19 genome is the ORF for a non-structural protein, NS1, which encodes a protein product of 7...

show abstract

Non-permissiveness of synovial membrane cells to human parvovirus B19 in vitro

Cited by 25 publications

References 25 publications

Parvovirus B19 Achievements and Challenges

Parvovirus B19 Achievements and Challenges

Lymphocyte recognition of human parvovirus B19 non-structural (NS1) protein: associations with occurrence of acute and chronic arthropathy?

Advances in the biology, diagnosis and host–pathogen interactions of parvovirus B19

Contact Info

Product

Resources

About